Core Viewpoint - Duorui Pharmaceutical (301075) has received approval from the National Medical Products Administration for the injection of Cefoperazone Sodium, indicating a significant development in its product portfolio [1] Company Summary - Duorui Pharmaceutical's wholly-owned subsidiary, Hubei Duorui Pharmaceutical Co., Ltd., has been granted a drug registration certificate for Cefoperazone Sodium injection, with specifications of 0.5g/1.0g [1] - The drug registration certificate is valid until June 9, 2030, with certificate numbers 2025S01726/2025S01727 and approval numbers H20254471/H20254472 [1] Industry Summary - Sales data from 2022 to 2024 for Cefoperazone Sodium injection shows revenue figures of 4.139 billion, 4.144 billion, and 3.078 billion respectively, indicating a slight decline in projected sales for 2024 [1]

二、药品其他情况 证券代码：301075 证券简称：多瑞医药 公告编号：2025-056 西藏多瑞医药股份有限公司 关于全资子公司获得药品注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 西藏多瑞医药股份有限公司（以下简称"公司"）全资子公司湖北 多瑞药业有限公司近日收到国家药品监督管理局核准签发的关于注 射用头孢唑肟钠的《药品注册证书》，现将有关信息公告如下： 药品名称 注射用头孢唑肟钠 主要成分 头孢唑肟钠 剂型 注射剂 规格 0.5g/1.0g 证书编号 2025S01726/2025S01727 药品批准文号 国药准字 H20254471/国药准字 H20254472 药品批准文号有 效期 至 2030 年 06 月 09 日 申请事项 药品注册（境内生产） 注册分类 化学药品 4 类 处方药/非处方药 处方药 上市许可持有人 名称：湖北多瑞药业有限公司 地址：湖北省荆州市公安县斗湖堤镇孱陵大道 生产企业 名称：深圳立健药业有限公司 地址：深圳市龙华区大浪街道上横朗社区园富路 1 号 一、药品基本情况 | | 根据《中华人民共和国药品管理 ...

证券代码：301075 证券简称：多瑞医药 公告编号：2025-055 | 序 | 购买 | 受托方名称 | 产品名称 | 金额 | 产品 | 产品起息 | 产品 | 预期年化 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 号 | 主体 | | | （万元） | 类型 | 日 | 到期日 | 收益率 | | 1 | 湖北多瑞药 | 恒丰银行股份有限 | 恒丰银行可转让 | 3,000 | 保本大 | 2025/6/11 | 2025/9/11 | 1.1000% | | | 业有限公司 | 公司武汉分行 | 单位大额存单 | | 额存单 | | | | 注：上述金额未扣除交易费用，下同。 西藏多瑞医药股份有限公司 关于使用暂时闲置募集资金进行现金管理到期赎回并继续进行现金 管理的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 西藏多瑞医药股份有限公司（以下简称"公司"）于 2024 年 10 月 23 日分别召开了第二届董事会第十六次会议、第二届监事会第十五 次会议审议通过了《 ...

Core Insights - The latest financing balance of the ChiNext market is 340.12 billion yuan, with a week-on-week increase of 1.03 billion yuan, indicating a positive trend in market financing activity [1][2] Financing Balance Overview - The total margin balance for ChiNext stocks reached 341.06 billion yuan, an increase of 1.04 billion yuan from the previous trading day, with the financing balance at 340.12 billion yuan, up by 1.03 billion yuan [1] - The margin balance for short selling was 93.7 million yuan, reflecting a week-on-week increase of 13.95 million yuan [1] Stocks with Increased Financing Balance - A total of 500 ChiNext stocks saw an increase in financing balance, with 36 stocks experiencing a growth rate exceeding 10% [1] - The stock with the highest increase in financing balance is Aoya Co., Ltd., with a latest financing balance of 65.55 million yuan, showing a week-on-week increase of 33.67% and a price increase of 20.00% on the same day [1][3] - Other notable stocks with significant financing balance increases include Fosa Technology and Hopson Co., Ltd., with increases of 28.81% and 26.58%, respectively [1][3] Market Performance of Stocks - Among the stocks with a financing balance increase of over 10%, the average price increase on the same day was 3.89%, with 26 stocks rising and two stocks, Aoya Co., Ltd. and Lepu Medical, hitting the daily limit [1] - Stocks with the largest price increases included Mankalon, Tianyuan Pet, and Xingyun Co., Ltd., with increases of 17.01%, 16.81%, and 15.34%, respectively [1] Stocks with Decreased Financing Balance - A total of 432 stocks experienced a decrease in financing balance, with 41 stocks showing a decline of over 5% [4] - The stock with the largest decrease in financing balance is Green Island Wind, with a latest financing balance of 22.39 million yuan, reflecting a decrease of 26.68% [4][5] - Other stocks with significant declines include Superjet Co., Ltd. and Kaile Co., Ltd., with decreases of 13.94% and 13.00%, respectively [4][5] Capital Flow Analysis - On June 4, among the stocks with increased financing balances, 29 stocks saw net inflows of main funds, with Lepu Medical, Kidswant, and Tianyuan Pet leading with net inflows of 391 million yuan, 70.54 million yuan, and 66.33 million yuan, respectively [2] - Conversely, seven stocks experienced net outflows, with Mankalon, Hopson Co., Ltd., and Langxin Group seeing the largest outflows of 58.55 million yuan, 31.15 million yuan, and 27.89 million yuan, respectively [2]

化学制药板块短线走低，华纳药厂跌超9%，天宇股份（300702）、舒泰神（300204）、多瑞医药 （301075）、海创药业等跟跌。 ...

关于使用暂时闲置募集资金进行现金管理的进展公告 | 本公司及董事会全体成员保证信息披露内容的真实、准确和完 | | --- | | 整，没有虚假记载、误导性陈述或重大遗漏。 | 证券代码：301075 证券简称：多瑞医药 公告编号：2025-054 西藏多瑞医药股份有限公司 注：上述金额未扣除交易费用，下同。 二、 关联关系说明 公司与上述委托理财的受托方不存在关联关系，公司本次进行现 金管理不涉及关联交易。 三、 投资风险分析及风险控制措施 公司进行现金管理购买的产品属于安全性高的投资品种，但不排 除该项投资受到市场波动的影响。针对可能发生的收益风险，公司制 定如下措施： 西藏多瑞医药股份有限公司（以下简称"公司"）于 2024 年 10 月 23 日分别召开了第二届董事会第十六次会议、第二届监事会第十五 次会议审议通过了《关于使用部分暂时闲置募集资金进行现金管理的 议案》，同意公司使用最高不超过人民币 32,000 万元（含本数）的闲 置募集资金进行现金管理，用于购买安全性高、流动性好、不影响公 司正常经营的理财产品。使用期限为自公司董事会审议通过之日起12 个月内，在上述使用期限及额度范围内，资金可循环 ...

Core Viewpoint - The latest financing balance of the ChiNext market is 339.346 billion yuan, with a week-on-week increase of 0.383 billion yuan, indicating a mixed performance among individual stocks in terms of financing balance changes [1][2]. Financing Balance Overview - As of May 26, the total margin balance of ChiNext stocks reached 340.278 billion yuan, an increase of 0.347 billion yuan from the previous trading day, with a financing balance of 339.346 billion yuan and a securities lending balance of 93.2 million yuan [1]. - A total of 447 stocks saw an increase in financing balance, with 26 stocks experiencing a growth of over 10% [1][3]. Notable Stocks with Increased Financing Balance - The stock with the highest increase in financing balance is Honggong Technology, which saw a financing balance of 63.481 million yuan, reflecting a week-on-week increase of 57.83% and a price increase of 2.51% [1][3]. - Other notable stocks with significant increases include Duorui Pharmaceutical and Demais, with increases of 47.30% and 39.00%, respectively [1][3]. Market Performance of Stocks with Increased Financing - Among the stocks with a financing balance increase of over 10%, the average price increase on that day was 0.88%, with 15 stocks rising [1][2]. - The top gainers included Xinbang Intelligent, Biaobang Co., and Chongde Technology, with increases of 16.16%, 8.95%, and 7.29%, respectively [1][2]. Stocks with Decreased Financing Balance - A total of 485 stocks experienced a decrease in financing balance, with 42 stocks showing a decline of over 5% [4]. - The stock with the largest decrease was Fusa Technology, with a financing balance of 47.5304 million yuan, reflecting a decline of 15.26% [4][5]. Notable Stocks with Decreased Financing Balance - Other significant decliners included Qide New Materials and Qushui Technology, with decreases of 14.99% and 13.09%, respectively [4][5]. - The overall trend indicates a mixed performance in the ChiNext market, with both increases and decreases in financing balances across various sectors [1][4].

Core Viewpoint - The A-share pharmaceutical sector is experiencing significant fluctuations, with notable declines in several companies' stock prices, indicating a broader market adjustment in this industry [1] Company Summary - Haichen Pharmaceutical has seen its stock price drop by over 10% [1] - Key competitors such as Keyuan Pharmaceutical and Tuoxin Pharmaceutical have also faced declines, with drops exceeding 8% [1] - Other companies in the sector, including Duori Pharmaceutical, Ruizhi Pharmaceutical, and Nuotai Biological, are also experiencing downward trends in their stock prices [1]

Group 1 - A-share pharmaceutical stocks are active at the beginning of trading, with Zhongsheng Pharmaceutical and Haisen Pharmaceutical hitting the daily limit [1] - Haichen Pharmaceutical, Huason Pharmaceutical, Taiji Group, and Duori Pharmaceutical also experienced gains [1]

Group 1 - The chemical pharmaceutical sector experienced a significant rally, with Hendi Pharmaceutical (301211) rising over 10% [1] - Xinhua Pharmaceutical (000756) reached its daily limit up [1] - Other companies such as Jinshi Yiyao (300434), Haichuang Pharmaceutical, and Duori Pharmaceutical (301075) also saw increases [1]